Novel nanoparticle vaccines for Listeriosis

Ricardo Calderon-Gonzalez¹, Marco Marradi², Isabel Garcia³, Nikolai Petrovsky⁴,⁵,¹ and Carmen Alvarez-Dominguez¹,³,⁴,*

¹Grupo de Genómica; Proteómica y Vacunas; Instituto de Investigación Marqués de Valdecilla; Santander, Spain; ²Fundacion Cidetec; Parque Tecnológico; San Sebastian, Spain; ³CIC-biomaGUNE; Parque Tecnológico; San Sebastian, Spain; ⁴Flinders University; Adelaide, Australia; ⁵Vaxine Ltd.; Flinders Medical Center; Adelaide, Australia

These authors equally contributed to this work.

In recent years, nanomedicine has transformed many areas of traditional medicine, and enabled fresh insights into the prevention of previously difficult to treat diseases. An example of the transformative power of nanomedicine is a recent nano-vaccine against listeriosis, a serious bacterial infection affecting not only pregnant women and their neonates, but also immune-compromised patients with neoplastic or chronic autoimmune diseases. There is a major unmet need for an effective and safe vaccine against listeriosis, with the challenge that an effective vaccine needs to generate protective T cell immunity, a hitherto difficult to achieve objective. Now utilizing a gold nanoparticle antigen delivery approach together with a novel polysaccharide nanoparticulate adjuvant, an effective T-cell vaccine has been developed that provides robust protection in animal models of listeriosis, raising the hope that one day this nanovaccine technology may protect immune-compromised humans against this serious opportunistic infection.

Listeriosis is caused by Listeria monocytogenes (Listeria), a bacterium that causes opportunistic infections of high-risk individuals including immune-compromised patients, pregnant women, new-borns and the elderly, resulting in high mortality even with timely antibiotic treatment. The most common listeriosis-related morbidities are abortions, premature birth, foetal malformations, meningitis, meningoencephalitis and septicaemia by virtue of Listeria’s ability to target to the central nervous system¹ and fetus. However, even individuals lacking risk factors can be affected by Listeria infection since it is a common food borne pathogen and a faecal carrier in 1–10% of the population.

Listeriosis occurs sporadically and in outbreaks, mainly through the ingestion of contaminated food or vertical mother-fetus transmission. In Europe there has been an increase in the number of listeriosis cases since 2008,²-⁴ with the last occurring in summer 2014 in Northern Spain with the cause being ingestion of contaminated food.² An increasing number of individuals within the population are susceptible to infection due to the increasing use of new biological immune-suppressive therapies for patients with chronic autoimmune disease, the aging of the population and hence the increasing number of elderly and immune-compromised patients.⁴ The detailed analysis of Listeria strains isolated from the last outbreak in northern Spain, showed a 10-fold increase in bacterial growth inside dendritic cells, compared to strains isolated in Spain 20 years ago⁵ and suggested that the character of human listeriosis might have undergone some modifications over this time. Unfortunately Listeria is not yet included on the Mandatory Notification System of microbes,⁶ making comprehensive studies of its epidemiology difficult. Nevertheless, the increasing number of serious cases of listeriosis urges the development of a vaccine to help in its control and prevention.

Conventional vaccination strategies against listeriosis using antigens or killed bacteria have been abandoned as they failed to induce significant T-cell responses required for protection. Listeria
live vector vaccines are also not an alternative since they represent a serious risk in immune-compromised individuals. Another important issue concerning listeriosis vaccines is that they need to induce simultaneous CD4$^+$ and CD8$^+$ T cell responses and be effective across the broad range of HLA haplotypes possessed by individuals at risk of listeriosis. While cellular dendritic cell (DC) vaccines loaded ex vivo with the Listeria GAPDH$_{1-22}$ peptide from glyceraldehyde-3-phosphate-dehydrogenase induced significant T-cell immunity and wide protection they are highly impractical and expensive to make, and thereby not suitable for routine human prophylactic vaccination. Hence better options are needed if a human vaccine against listeriosis is ever to be achieved.

Nanomedicine offers versatile tools for infectious diseases with nanomaterials having been used to develop vaccines and antibacterial agents. Multivalent glycoconjugates based on gold glyconanoparticles (GNP) which allow multiple interactions between their sugars and cell surface receptors represent an appealing vaccine delivery technology. Major GNP advantages are their easy handling, resistance to enzymatic degradation, water solubility, convenient antigen loading, immune cell targeting, lack of toxicity and small size around 2 nanometers. They were therefore used to generate a Listeria based GNP nanovaccine by covalent linking of glucose and a peptide representing the Listeria T-cell epitope (LLO$_{91-99}$) to the GNP metallic core thereby creating GNP-LLO$_{91-99}$ nanoparticles. The aim was to improve upon the effectiveness previously seen with a DC vaccine loaded with LLO$_{91-99}$ peptide that induced CD8 T-cell responses and IFN-γ levels but only modest Listeria protection. The GNP-LLO$_{91-99}$ nanovaccine was shown to be free of cytotoxicity, effectively delivered the Listeria epitope to DC in vitro and in vivo and induced effective CD8$^+$ T-cell immunity. Unfortunately, listeriosis protection with the LLO$_{91-99}$ nanovaccine was only partial and inferior to that obtained with a DC vaccine loaded with GNP-LLO$_{91-99}$. Consequently, the GNP-LLO$_{91-99}$ nanovaccine was combined with the novel polysaccharide nanoparticle advat,$^{TM}$ an adipovaccine derived from delta inulin microparticles that has previously been shown to be effective and safe in human trials of influenza and hepatitis B vaccines and has been shown to induce robust CD4$^+$ and CD8$^+$ T-cell responses. GNP-LLO$_{91-99}$ nanovaccines formulated with Advat,$^{TM}$ had markedly enhanced T-cell immunogenicity and conferred listeriosis protection to levels previously only achieved with in vivo DC loaded vaccines. Notably, the frequency of activated DC doubled when Advat,$^{TM}$ adjuvant was added to the nanovaccine, together with significantly increased IL-12 production. Furthermore, Advat,$^{TM}$ incorporation resulted in robust Listeria-specific CD4 and CD8 T-cell responses after a Listeria challenge. Thus, Advat,$^{TM}$ induced epitope spreading to the GNP-LLO$_{91-99}$ nanovaccine resulting post-Listeria challenge in T-cell recognition of other Listeria epitopes not present in the vaccine.

In summary, a GNP-LLO$_{91-99}$ nanovaccine combined with the novel polysaccharide adjuvant provided unique in vivo DC targeting and induction of robust T-cell responses. This translated into robust protection against Listeria challenge not previously achievable except with a complex and expensive in vivo DC loaded vaccine approach. This offers the first opportunity to produce a cheap and reliable Listeria vaccine for use as a conventional prophylactic vaccine for all individuals at risk of listeriosis. It could also be potentially useful as an immune potentiating vaccine for already infected patients, although this use must await studies of its effectiveness in already infected models. This novel nanovaccine shows the potential for nanomedicine to transform vaccine development and help solve longstanding problems including the need for an effective vaccine platform able to generate protective T-cell responses.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References
1. Frande-Cabanes E, Fernandez-Prieto L, Calderon-Gonzalez R, Rodriguez-Del Rio E, Yaíñez-Díaz S, Fanaraga ML, Alvarez-Dominguez C. Dissoication of Innate Immune Responses in Microfluidic Infected with Listeria monocytogenes. Glia 2014; 62:233-46; PMID:24311463; http://dx.doi.org/10.1002/glia.22682
2. Pérez-Trallero E, Zigorraga C, Artieda J, Alkorta M, Marimón JM. Two outbreaks of Listeria monocytogenes infection, Northern Spain. Emerg Infect Dis 2014; 20(12):2155-7; http://dx.doi.org/10.3201/eid2012.140993
3. Perea-Sagredo JL, Hernández MV, Fernandez-Llano N, Giménez-Ubeda E, Muñoz-Fernández S, Ortiz A, González-Gay MA, Fariñas MC, Białosadzer Group. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol 2008; 26(5):854-9
4. Hernandez-Milian A, Payeras-Cife F, A what is new in listeriosis? Biomed Res Int 2014; 2014:58051; PMID:24822197; http://dx.doi.org/10.1155/2014/58051
5. Calderon-Gonzalez R, Cilla G, Alkorta M, Perez-Trallero E and Alvarez-Dominguez C. Listeriosis outbreaks and their growth in immune cells. 2015 (manuscript in preparation)
6. Párrilla-Valero F, Vaque-Rafart J. Study of Listeriosis incidence in Spain. Gan Sanitat 2014; 28(1):74-6; http://dx.doi.org/10.1016/j.gascn.2013.03.004
7. Calderón-Gonzalez R, Frande-Cabanes E, Bronchalo-Vicente L, Lecca-Cuello ML, Pareja J, BolsMartínez A, Fanaraga ML, Yaíñez-Díaz S, Carrasco-Marín E, Alvarez-Dominguez C. Cellular vaccines in listeriosis: role of the Listeria antigen GAPDH. Front Cell Infect Microbiol 2014; 4(22):1-11; http://dx.doi.org/10.3389/fcimb.2014.00022
8. Calderon-Gonzalez R, Frande-Cabanes E, Torres M, Pareja E, Alaez-Alvarez L, Alvarez-Dominguez C. A dendritic cell-targeted vaccine loaded with glyceraldehyde-3-phosphate dehydrogenase peptides proposed for individuals at high risk of listeriosis. J Vaccines Vaccines 2015; 6;266):1-8; http://dx.doi.org/10.14721/2157-7560.1000266
9. Calderon-Gonzalez R, Torres M, Pareja E, Frande-Cabanes E, Potrovsky N, Alvarez-Dominguez C. Identification and characterisation of T-cell epitopes for incorporation into dendritic cell-delivered Listeria vaccines. J Immunol Methods 2015 May 29; pii: S0022-1751(15)00020-8; doi:10.1016/j.jim.2015.05.009
10. Pion M, Serramia MJ, Diaz L, Bryzewska M, Gallart T, Garcia F, Gómez R, de la Mata FJ, Muñoz-Fernandez MA. Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. Biomaterials 2010; 31(33):8749-58; PMID:20832111; http://dx.doi.org/10.1016/j.biomaterials.2010.07.093
11. Di Giamvincenzo P, Calvo J, Perez S, Bedoya LM, Alcamos MC, Biobadaser Group. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol 2008; 26(5):854-9
12. Safari D, Marradi M, Chiado F, Dekker HATh, Shan Y, Adamo R, Occason S, Rijkers GT, Lahmann M, Kamelei ng JP, Penadés S, Snippe H. Gold nanoparticles as multifunctional and multimodal carbohydrate systems. Chem Soc Rev 2013; 42: 4728-4745.
13. de la Fuente JM, Penadés S. Glyconanoparticles: types, synthesis and applications in glycoscience, biomedical and material science. Biochim Biophys Acta 2006; 1760(4):636-51; PMID:16529864; http://dx.doi.org/10.1016/j.bbagen.2005.12.001
14. de la Fuente JM, Barrientos AG, Rojas TC, Rojo J, Cahuza J, Fernández A, Penadés S. Gold glyconanoparticles as water-soluble polyvalent models to study...
carbohydrate interactions. Angew Chem Int Ed 2001; 40(12):2257-61; http://dx.doi.org/10.1002/1521-3773 (20010618)40:12<2257::AID-ANIE2257>3.0.CO;2-S

16. Marradi M, Chiodo F, García I, Penadés S. Glyconanoparticles as multifunctional and multimodal carbohydrate systems. Chem Soc Rev 2013; 42:4728; PMID:23288339; http://dx.doi.org/10.1039/c2cs35420a

17. Rodriguez-Del Río E, Marradi M, Calderón-González R, Fronde-Cabanes E, Penadés S, Petrovsky N, Alvarez-Dominguez C. A gold glyco-nanoparticle carrying a listeriolyisin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection. Vaccine 2015; 33(12):146573; PMID:2569260; http://dx.doi.org/10.1016/j.vaccine.2015.01.062

18. Kono M, Nakamura Y, Suda T, Uchio M, Tsujimura K, Nagata T, Giermasz AS, Kalinski P, Nakamura H, Chida K. Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine. Vaccine 2012; 30:2633-9; PMID:22365841; http://dx.doi.org/10.1016/j.vaccine.2012.02.026

19. Gordon DL, Saikov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzl S, Petrovsky N. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. Vaccine 2012; 30(36):5407-16; PMID:22717330; http://dx.doi.org/10.1016/j.vaccine.2012.06.009

20. Gordon D, Kelley P, Heinzl S, Cooper P, Petrovsky N. Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase I study. Vaccine 2014; 32(48):6469-77; PMID:25267153; http://dx.doi.org/10.1016/j.vaccine.2014.09.034

21. Cristillo AD, Ferrari MG, Hudacik I, Lewis B, Galmin L, Bowen B, Thompson D, Petrovsky N, Markham P, Pal R. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1 vaccine formulations. J Gen Virol 2011; 92(Pr 1):128-40; PMID:21169215; http://dx.doi.org/10.1099/vir.0.023242-0

22. Honda-Okubo Y, Saade F, Petrovsky N, AdvaxTM, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 2012; 305373-81; PMID:22728225; http://dx.doi.org/10.1016/j.vaccine.2012.06.021